Urologix Inc. | Cash Flow

Fiscal year is July-June. All values USD Thousands.
2010
2011
2012
2013
2014
Net Income before Extraordinaries
2,169.00
3,733.00
4,695.00
4,292.00
7,608.00
Depreciation, Depletion & Amortization
793.00
565.00
695.00
674.00
587.00
Other Funds
489.00
335.00
812.00
566.00
4,364.00
Funds from Operations
887.00
2,833.00
3,153.00
3,051.00
2,693.00
Changes in Working Capital
368.00
463.00
2,440.00
1,092.00
1,163.00
Net Operating Cash Flow
1,255.00
2,370.00
713.00
1,959.00
1,530.00
Capital Expenditures
85.00
272.00
57.00
79.00
42.00
Net Investing Cash Flow
85.00
275.00
565.00
1,479.00
42.00
Net Financing Cash Flow
10.00
4.00
116.00
3,829.00
-
Net Change in Cash
1,330.00
2,641.00
1,162.00
391.00
1,572.00
Free Cash Flow
1,336.00
2,642.00
770.00
2,038.00
1,562.00
Deferred Taxes & Investment Tax Credit
-
-
35.00
1.00
36.00
Net Assets from Acquisitions
-
-
500.00
1,368.00
-
Change in Capital Stock
10.00
4.00
116.00
3,829.00
-
Other Uses
-
3.00
8.00
32.00
-

About Urologix

View Profile
Address
14405 21st Avenue North
Minneapolis Minnesota 55447
United States
Employees -
Website -
Updated 07/08/2019
Urologix, Inc. develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia. The company was founded by Mitchell Dann and John M. Reid on May 29, 1991 and is headquartered in Minneapolis, MN.